Mexidol in complex treatment of glaucoma

FGU «MNII GB named after Gelmgoltsa Rosmedbiotechnology»
Department of Ophthalmology of Medical Faculty
GBOU VPO RNIMU Russian National Research Medical University

Purpose: to evaluate efficiency and safety of Mexidol solution in complex treatment in patients with POAG of I–III stages. Materials and methods: patients with POAG I–III stages with compensated IOP level (not more than 21 mmHg) were included into the study. All patients were divided into 3 groups: in 1st group Mexidol was prescribed on the background of standard treatment by 100 mg per day intramuscularly, in the 2nd group – on the background of standard treatment by 300 mg per day intramuscularly, 3rd group received standard treatment (picamilonum – by 1 tablet 3 times per day). Patients with I–II stages of glaucoma received treatment during 14 days, with III stage – 21 days. Evaluation of treatment effect was carried out in 30 days after it’s start. External eye examination, visometry, biomicroscopy, ophthalmoscopy, tonometry, computer perimetry, electrophysiologic examination, arterial pressure and heart rate measurements were proceeded on the first, intermediate and last control visits. Results: Visual acuity was improved in 1st and 2nd group more evidently than in the 3rd one. There was a tendency of improvement of the condition of the visual field (decreasing of the scotoma amount in patients which received Mexidol by 100 mg per day). Increased at the beginning electrosensitivity threshold in patients with I–III stages of glaucoma reduced by the end of the study, and decreased level of the electrical lability of optic nerve raised. Dosage of 300 mg per day was found more efficient than 100 mg per day. Conclusion: Mexidol could be recommended for inclusion into the complex treatment of patients with glaucomatous neuropathy.